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Evidence for a Direct Harmful Effect of Alcohol on Myocardial Health:
A Large Cross-Sectional Study of Consumption Patterns and
Cardiovascular Disease Risk Biomarkers From Northwest Russia,
2015 to 2017
Olena Iakunchykova, MS; Maria Averina, MD, PhD; Alexander V. Kudryavtsev, MPH, PhD; Tom Wilsgaard, PhD; Andrey Soloviev, MD, PhD;
Henrik Schirmer, MD, PhD; Sarah Cook, MD, PhD; David A. Leon, PhD
Background-—Alcohol drinking is an increasingly recognized risk factor for cardiovascular disease. However, there are few studies
of the impact of harmful and hazardous drinking on biomarkers of myocardial health. We conducted a study in Russia to investigate
the impact of heavy drinking on biomarkers of cardiac damage and inﬂammation.
Methods and Results-—The Know Your Heart study recruited a random sample of 2479 participants from the population of
northwest Russia (general population) plus 278 patients (narcology clinic subsample) with alcohol problems. The general
population sample was categorized into harmful drinkers, hazardous drinkers, nonproblem drinkers, and nondrinkers, according to
self-reported level of alcohol consumption, whereas the narcology clinic sample was treated as the separate group in the analysis.
Measurements were made of the following: (1) high-sensitivity cardiac troponin T, (2) NT-proBNP (N-terminal pro-B-type natriuretic
peptide), and (3) hsCRP (high-sensitivity C-reactive protein). The narcology clinic subsample had the most extreme drinking pattern
and the highest levels of all 3 biomarkers relative to nonproblem drinkers in the general population: high-sensitivity cardiac
troponin T was elevated by 10.3% (95% CI, 3.7%–17.4%), NT-proBNP by 46.7% (95% CI, 26.8%–69.8%), and hsCRP by 69.2% (95% CI,
43%–100%). In the general population sample, NT-proBNP was 31.5% (95% CI, 3.4%–67.2%) higher among harmful drinkers
compared with nonproblem drinkers. Overall, NT-proBNP and hsCRP increased with increasing intensity of alcohol exposure (test of
trend P<0.001).
Conclusions-—These results support the hypothesis that heavy alcohol drinking has an adverse effect on cardiac structure and
function that may not be driven by atherosclerosis. ( J Am Heart Assoc. 2020;9:e014491. DOI: 10.1161/JAHA.119.014491.)
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A lcohol drinking is increasingly recognized as a risk factorfor cardiovascular disease (CVD).1 Alcohol, even when
consumed in moderation, is associated with complex changes
in blood biochemistry, involving changes in many biomarkers
for cardiometabolic risk.2 Binge drinking is associated with
alcoholic cardiomyopathy, high blood pressure, increased risk
of myocardial infarction, arrhythmias, and fatal cardiac arrest
and stroke.3 However, the causal nature of many of the
associations between heavy alcohol use and CVD biomarkers
as well as the mediation pathways between alcohol use and
cardiovascular outcomes are not fully understood. In partic-
ular, it is unclear whether any effect is through alcohol’s effect
on the atherosclerotic process in vessels as distinct from
direct toxic damage to the myocardium.
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Levels of blood-based cardiovascular biomarkers can be
used as proxy measures of cardiovascular health. High-
sensitivity cardiac troponin T (hs-cTnT) and NT-proBNP (N-
terminal pro-B-type natriuretic peptide) were both developed
for use in clinical cardiology and are now increasingly used in
population-based studies of CVD. When evaluating general
population cohorts, any concentration of hs-cTnT >3 ng/L
has been associated with subclinical CVD and has adverse
prognostic implications.4 Cardiac wall stretch biomarker NT-
proBNP has been mostly used for diagnosis of heart failure
and for prognosis in the setting of heart failure.5 However, in
population-based samples, low-grade elevation in NT-proBNP
was shown to be an early marker of cardiac injury that is not
yet clinically evident.6 Assessment of natriuretic peptides can
predict ﬁrst-onset heart failure or improve prediction of
coronary heart disease in people without known CVD.7 In
addition, NT-proBNP concentration predicted stroke as
strongly as a diagnosis of coronary heart disease. This could
partly be explained by associations between NT-proBNP
concentration and stroke risk factors: left ventricular hyper-
trophy and atrial ﬁbrillation.7–9
There has been substantial interest in CRP (C-reactive
protein) as a risk predictor related to the underlying inﬂamma-
tory nature of atherosclerosis,10 although there is evidence that
it is in itself not causal but may instead be a marker of a general
inﬂammatory disease process.11 A 1000-fold elevation of CRP
is indicative of acute inﬂammation,12 whereas lower persistent
elevation of hsCRP (high-sensitivity C-reactive protein) may be
caused by low-grade systemic inﬂammatory processes asso-
ciated with atherosclerosis.13 Increased levels of hsCRP have
been predictive of future cardiovascular events14,15 and have
been associated with coronary plaque burden.16
Previous research has looked at the relationship of
biomarkers with classic risk factors for CVD, among them
smoking, obesity indexes, blood pressure, and lipid
proﬁles.13,17–20 However, there has been little work on the
association of alcohol with biomarkers of heart damage,
cardiac wall stretch, and systemic low-grade inﬂammation.
Most of the published work was done in the populations with
relatively moderate levels of alcohol consumption,18,21–23 with
the exception of one study that showed prospectively an
association between heavy drinking and heart failure in
vulnerable men with underlying myocardial ischemia.24 As
noted elsewhere, there is a gap in the research literature on
heavy drinking patterns affecting cardiovascular outcomes.25
Russia is one of the countries that has had a tradition of
heavy drinking of spirits and has been characterized as having a
particularly harmful drinking proﬁle.1 Studies of CVD biomark-
ers in the Russian population make it possible to achieve 2
goals: (1) to investigate the mechanisms by which hazardous
and harmful patterns of alcohol use increase the risk of
cardiovascular outcomes and (2) to help clarify the role of heavy
alcohol use in explaining why Russia has one of the highest CVD
rates of any country.26 In this study, we used measures of hs-
cTnT, NT-proBNP, and hsCRP to assess the damage to
myocardium, cardiac wall stretch, and general low-grade
inﬂammation in heavy drinking individuals recruited through
state-run facilities for treatment of alcohol use disorders and in
a large general population sample in Russia categorized
according to level and pattern of alcohol use.
Methods
Requests to access the data set from bona ﬁde researchers
may be sent to the International Project on Cardiovascular
Disease in Russia.27
Study Design
The Know Your Heart study recruited 2479 participants from
the general population of the city of Arkhangelsk in northwest
Russia from 2015 to 2018. A detailed account of the rationale
and description of the methods of the study has been
published previously.28 At the same time, we recruited 278
patients from the Arkhangelsk Regional Psychiatric Hospital
with a primary diagnosis of alcohol problems.28 The latter
group is referred to subsequently as the narcology clinic
subsample, consistent with Russian terminology. The study
sample was almost exclusively of European descent.
Ethical Approval
All procedures performed were in accordance with the ethical
standards of the institutional research committee (ethics
committees of the London School of Hygiene and Tropical
Medicine [London, UK] and the Northern State Medical
Clinical Perspective
What Is New?
• In the population-based study, we observed elevated levels
of markers of heart damage, cardiac wall stretch, and
general inﬂammation among heavy alcohol users compared
with nonproblem drinkers.
• Heavy drinking was conﬁrmed as an important risk factor of
cardiovascular disease, with probable direct effect on
cardiac structure and function.
What Are the Clinical Implications?
• Prevention of cardiovascular diseases in the general pop-
ulation should include screening and intervening on harmful
and hazardous alcohol use.
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University [Arkhangelsk, Russia]) and with the 1964 Declara-
tion of Helsinki and its later amendments or comparable
ethical standards. All participants included in the analysis
gave signed informed consent.
Study Participants
The general population sample from Arkhangelsk was recruited
at random (stratiﬁed by age, sex, and district of residence) using
the regional health insurance fund register as the sampling
frame. Trained interviewers visited the addresses selected and
invited the appropriate resident at each address to take part in
the study. A minimum of 3 attempts were made to get a
response from each address. When successful, an interview
was conducted about circumstances, health, and behaviors of
the participant. The response rate was 68% of the addresses
where contact with a person of the target age and sex was
established, and 96% of those interviewed took part in a
subsequent health check.28
In addition, a sample of heavy drinkers (narcology clinic
subsample) were recruited from inpatients at the regional
psychiatric hospital. The inclusion criteria were as follows: age
of 35 to 69 years, resident in the city of Arkhangelsk or
Arkhangelsk region, and admitted to the narcological depart-
ment of the regional psychiatric hospital with a primary
diagnosis related to alcohol drinking. People with ≥1 of the
following characteristics were excluded:
1. Experiencing alcohol withdrawal symptoms or during the
ﬁrst week of alcohol detoxiﬁcation;
2. Behavior that suggested that an individual could pose a
threat to the safety of the clinic staff or other participants
during the survey;
3. Current or past misuse of drugs other than nicotine or
alcohol;
4. Unable to give informed consent for participation in the
study (eg, severe cognitive deﬁcit or acute psychiatric
illness).
Clinicians at the hospital used their judgement to decide
which participants should or should not be invited. Signed
informed consent was obtained. A total of 278 patients were
recruited of 322 patients invited (85.4%).
We analyzed data on 2354 participants from the general
population in Arkhangelsk plus 271 individuals from the
narcology clinic subsample who attended the health check
and for whom blood analyte concentrations were available.
Data and Sample Collection
The baseline interview was administered by a trained
interviewer using a tablet computer-assisted personal
interviewing device. For the general population sample, the
interview was done in people’s homes in nearly all cases. For
the narcology clinic subsample, it was done at the
Arkhangelsk Regional Psychiatric Hospital by the same set
of trained interviewers. Information was collected on medical
history and socioeconomic circumstances, education, and
lifestyle.
The subsequent health check comprised a physical exam-
ination (including blood pressure, height, waist and hip
circumference, and weight) and blood sample collection.
Participants were requested not to eat or drink alcohol in the
4 hours before their appointment. Participants in the narcol-
ogy clinic subsample were transported to the research clinic
for the health check, accompanied by a nurse. A second
interview was conducted at this stage that recorded medical
history, use of medications, alcohol use, and smoking.
A total of 50 mL of blood was taken from each participant.
Samples were centrifuged, and serum was transferred to
barcoded 1.8-mL cryovials and frozen (80°C) within 2 hours
after venipuncture. These were subsequently shipped to a
laboratory in Moscow, where they were stored at 80°C and
then analyzed in a single batch at the end of the ﬁeldwork.
The laboratory staff were blind to all characteristics of
participants, including whether serum was from the narcology
clinic subsample or the general population sample.
Outcome Variables
hs-cTnT and NT-proBNP were measured using a high-
sensitivity electrochemiluminescence immunoassay (Roche
Diagnostics GmbH, Hitachi, Japan) on a Cobas e411 analyzer.
hsCRP was measured using a high-sensitivity immunoturbidi-
metric test on AU 680 Chemistry System Beckman Coulter.
The lower limit of detection for hs-cTnT test was 3 ng/L, and
54 participants (2.07%) with values below the limit of
detection had their values recoded to 2.9 ng/L. The limit of
detection of NT-proBNP test was 5 ng/L, and NT-proBNP
values of 19 participants (0.7%) with values below the limit of
detection were recoded to 4.9 ng/L. Because we were
interested in low-grade inﬂammation that is not caused by
acute infection, 38 participants with hsCRP values >99th
percentile for the general population (30 mg/L) were
excluded from the statistical analysis of hsCRP.
Exposure Variables
We deﬁned 2 categorical exposure variables. The ﬁrst was
binary and divided the study group into those from the
narcology clinic subsample and those from the general
population sample. The second exposure variable further
categorized the general population sample into groups based
on self-report of various dimensions of alcohol consumption.
Those who reported not drinking alcoholic beverages during
DOI: 10.1161/JAHA.119.014491 Journal of the American Heart Association 3
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the past 12 months at baseline interview and health check
were classiﬁed as nondrinkers. The categories of harmful and
hazardous drinkers were deﬁned using 3 instruments: the
validated Russian-language translations of the Alcohol Use
Disorders Identiﬁcation Test,29 the Cut down, Annoyed, Guilty,
Eye Opener (CAGE) instrument,30 and questions on alcohol
drinking pattern previously found to be highly predictive of
mortality in Russia.31,32 The Alcohol Use Disorders Identiﬁca-
tion Test is a screening test for hazardous and harmful
drinking, whereas CAGE is used to screen for alcoholism in
clinical settings. The CAGE score was adapted to have a
reference period of the past 12 months rather than ever in a
participant’s lifetime, in keeping with a previous study from
Russia because of interest in alcohol use in the recent past.33
The scheme for categorizing the general population sample
into 4 groups is presented in the Figure.
To validate the approach chosen for classiﬁcation of the
general population sample into drinking categories, we used
the following: (1) information on alcohol volume consumed
during the past 12 months, calculated using the standard
quantity frequency approach34; (2) history of asking for help
with alcohol problems from social workers or physicians; and
(3) blood biomarkers of alcohol use. c-Glutamyl transferase
and carbohydrate-deﬁcient transferrin (CDT) are biomarkers
of excessive drinking.35 We used a previously developed
approach36 to calculate a combined biomarker value of ɣ-%
CDT=[0.89ln(c-glutamyl transferase)]+[1.39ln(%CDT)], with a
cutoff value of 4.0 for heavy drinking. c-Glutamyl transferase
was measured in all study participants. Because of cost, CDT
was not assayed in everyone. It was measured in all 271
patients receiving treatment for alcohol problems, all 400
problem drinkers (Alcohol Use Disorders Identiﬁcation Test
score ≥8 or CAGE score ≥2), all 143 nonproblem drinkers
drinking >5 L per year, and 244 randomly selected non-
drinkers and nonhazardous drinkers. The combined ɣ-%CDT
was thus only available for 1032 participants. As this
biomarker was only used to establish the face validity of the
alcohol categorization, the fact that it was only available for a
subset of study subjects did not affect the numbers used in
the main analyses.
Other Covariates
Information was available on classic risk factors, including
those that are on the potential causal pathway between
alcohol use and CVD biomarkers. We constructed directed
acyclic graphs to identify the minimal sufﬁcient adjustment
set of variables for estimating the total effect of alcohol use
(Figures S1 through S3). These were age, sex, smoking, and
education. Education was classiﬁed into 4 categories: incom-
plete secondary or lower; secondary or professional school;
incomplete higher or specialized secondary (eg, medical,
Category of drinker Drinking 
alcoholic 
beverages 
during last 12 
month
AUDIT>=8 CAGE>=2 Harmful 
Russian 
drinking 
pattern *
General population sample
Harmful drinker ✔ ✔ ✔ ✔
Hazardous drinker ✔ ✔ for one or two instruments
Non-problem drinker ✔ ✘ ✘ ✘
Non-drinker ✘ ✘ ✘ ✘
Figure. The assignment scheme of the general population sample into categories by drinking status: (1)
harmful drinkers, (2) hazardous drinkers, (3) nonproblem drinkers, and (4) nondrinkers. *Twice weekly or
more frequency of hangover and/or excessive drunkenness and/or sleeping in clothes at night because of
drunkenness and/or failing their family or personal obligations because of drinking and/or drinking
nonbeverage alcohols (sources of ethanol not intended for drinking, such as medicinal tinctures) and/or ≥1
episodes of zapoi (a period of ≥2 days of being drunk, during which a participant is withdrawn from normal
social life).32 AUDIT indicates Alcohol Use Disorders Identiﬁcation Test; GAGE, Cut down, Annoyed, Guilty,
Eye Opener.
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teacher training college, or technical); and higher (university).
Professional schools include institutions that provide profes-
sional training but no degree. Smoking status was categorized
as current smokers, ex-smokers, and never smokers. For
current smokers, the number of cigarettes smoked was
speciﬁed as 1 to 10/day, 11 to 20/day, and >20/day.
Other variables used in the analysis included potential
mediators. These included systolic and diastolic blood pres-
sure (mean of second and third measurements) and use of
antihypertensives, determined according to recorded
medications coded to the Anatomical Therapeutic Chemical
classiﬁcation as C02 (antihypertensives), C03 (diuretics), C07
(b-blocking agents), C08 (calcium channel blockers), or C09
(agents operating on the renin-angiotensin system). A small
proportion of participants self-reported use of blood
pressure–lowering medication without a corresponding
Anatomical Therapeutic Chemical code being found. These
participants were also deﬁned as being on antihypertensives.
Body mass index (BMI) was calculated as weight (in
kilograms) divided by height (in meters) squared. Waist/hip
ratio was the mean of 2 measurements of waist divided by the
mean of 2 measurements of hip. The blood lipid proﬁle was
measured and included total cholesterol, low-density lipopro-
tein cholesterol, high-density lipoprotein cholesterol,
apolipoprotein A1, and apolipoprotein B. Renal function was
assessed by measuring cystatin C and estimated glomerular
ﬁltration rate using the Chronic Kidney Disease Epidemiology
Collaboration cystatin C equation.37
Statistical Analyses
Descriptive tabulations of participant characteristics were age
and sex standardized to the Standard European Population
2013. hs-cTnT, NT-proBNP, and hsCRP had right-skewed
distributions and were ln transformed for analysis.
We assessed the association between alcohol use and
biomarkers of CVD (hs-cTnT, NT-proBNP, and hsCRP) by
comparing geometric mean levels of biomarkers in the
narcology and general population samples. Next, we compared
means of ln-transformed biomarkers across the categories of
alcohol consumption: (1) narcology clinic subsample; (2)
general population sample, harmful drinking pattern; (3) general
population sample, hazardous drinking pattern; (4)
general population sample, nonproblem drinkers; and (5)
general population sample, nondrinkers. This approach allowed
a nuanced assessment of CVD biomarkers, depending on the
drinking pattern, separating nonproblem drinkers as a compar-
ison group and determining if therewas an increasing trendwith
increased intensity of alcohol use.
The sociodemographic characteristics and CVD risk
factors were compared by the categories of main exposure
variable using heterogeneity tests adjusting for age and sex in
generalized linear models. The associations between alcohol
use and ln-transformed biomarkers of CVD (hs-cTnT, NT-
proBNP, and hsCRP) were assessed using multivariable
adjusted linear regression models. Age was included in the
model as a continuous variable. Quadratic and cubic terms
were added to account for nonlinearity and kept in the modelif
associated with an outcome at P<0.05. Model 1 involved
adjustment for age and sex. Model 2 adjusted for potential
confounders (age, sex, smoking, and education). Model 3
additionally included possible mediators (waist/hip ratio, BMI,
lipids [low-density lipoprotein, high-density lipoprotein, and
apolipoprotein B/apolipoprotein A1 ratio], blood pressure
[systolic and diastolic], use of blood pressure medication, and
estimated glomerular ﬁltration rate). This ﬁnal model pro-
vided an estimate for the direct effect of alcohol on cardiac
damage, cardiac wall stretch, and low-grade inﬂammation. A
test for increasing linear trend in means of biomarkers across
the categories of alcohol exposure was done with df=1. To
make the regression coefﬁcients more interpretable and
comparable, they were back transformed and presented as
percentage of difference in mean compared with the
reference category (nonproblem drinkers). Statistical analysis
was performed using SAS software 9.4 (SAS Institute Inc,
Cary, NC).
Results
The descriptive characteristics of the narcology clinic sub-
sample and the general population sample (age and sex
standardized) are presented in Table 1. The average age of
the narcology clinic subsample was 48.5 years and that of the
general population sample was 53.7 years. The narcology
clinic sample was 76.8% men, and the general population
sample was 41.7% men. On average, the narcology clinic
subsample had lower systolic blood pressure (potentially
because of clinical management during hospital admission),
lower low-density lipoprotein and total cholesterol values,
lower BMI and waist circumference, and lower estimated
glomerular ﬁltration rate compared with the general popula-
tion sample. A much higher proportion of narcology clinic
subsample compared with the general population sample
were current smokers. Detectable hs-cTnT was observed in
98% of participants, whereas the equivalent ﬁgure for NT-
proBNP was 99%. The geometric means for hs-cTnT, NT-
proBNP, and hsCRP were signiﬁcantly higher in the narcology
clinic subsample compared with the general population
sample.
The face validity of our categorization of alcohol use is
demonstrated in Table 2. This shows indicators of drinking for
each of the drinking categories derived from self-reported
alcohol use in the general population and the narcology clinic
sample. Almost all of the alcohol measures show a clear trend
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across the categories. The concentration of alcohol use
biomarkers (CDT and c-glutamyl transferase) and the propor-
tion of the participants with an elevated combined biomarker
of alcohol use are highest in harmful drinkers, intermediate in
hazardous drinkers, and lowest in nonproblem drinkers.
Similarly, the volume of alcohol consumed by drinkers during
the past year and the amount of alcohol consumed per day
are highest in harmful drinkers, intermediate in hazardous
drinkers, and lowest in nonproblem drinkers. Of the 227
nondrinkers, 82 were former drinkers, as distinct from life-
long nondrinkers.
CVD Biomarkers in the Narcology Clinic
Subsample Versus the General Population
After adjustment for age, sex, smoking, and education, the
levels of all biomarkers (hs-cTnT, NT-proBNP, and hsCRP) were
higher in the narcology clinic subsample compared with the
general population sample as a whole (Table 3). Speciﬁcally,
hs-cTnT was higher by 12.3% (95% CI, 5.9%–19.1%) and NT-
proBNP was higher by 43.9% (95% CI, 25.4%–65.1%), whereas
hsCRP was higher by 66.0% (95% CI, 41.7%–94.5%).
CVD Biomarkers Across 5 Categories of Alcohol
Use
Consistent with the previous analysis, compared with non-
problem drinkers in the general population sample, the
narcology clinic subsample had much higher levels of hs-cTnT,
NT-proBNP, and hsCRP (Table 4).
hs-cTnT was elevated by 10.3% (95% CI, 3.7%–17.4%) in the
narcology clinic subsample compared with the nonproblem
drinkers in the general population, controlling for sex, age,
smoking, and education. However, hs-cTnT levels were lower
in the group of harmful drinkers in the general population
compared with nonproblem drinkers. Adjustment for the
Table 1. Age- and Sex-Standardized Means and Proportions With 95% Conﬁdence Intervals (n=2625)
Variables
Narcology Clinic
Subsample (n=271)
General Population
Sample (n=2354)
P Value, Test of
Heterogeneity
Current drinkers* 1.00 0.91 (0.89–0.92) <0.001
Harmful Russian drinking pattern† 0.89 (0.85–0.93) 0.08 (0.07–0.09) <0.001
AUDIT score ≥8 0.95 (0.90–1.00) 0.16 (0.15–0.18) <0.001
CAGE score ≥2 0.92 (0.87–0.98) 0.15 (0.14–0.16) <0.001
Current smoking 0.75 (0.68–0.82) 0.26 (0.25–0.28) <0.001
Use of antihypertensive medication 0.33 (0.26–0.40) 0.39 (0.37–0.41) 0.102
BMI, mean, kg/m2 25.3 (24.5–26.2) 27.6 (27.3–27.8) <0.001
Waist/hip ratio, mean 0.90 (0.89–0.91) 0.89 (0.88–0.89) 0.028
Waist, mean, cm 86.9 (84.8–88.9) 91.2 (90.7–91.7) <0.001
Systolic blood pressure, mean, mm Hg 127 (124–130) 132 (131–132) 0.006
Diastolic blood pressure, mean, mm Hg 83.6 (81.8–85.4) 83.5 (83.1–84.0) 0.95
Total cholesterol, mean, mmol/L 5.15 (4.98–5.32) 5.37 (5.33–5.42) 0.012
LDL cholesterol, mean, mmol/L 3.43 (3.29–3.57) 3.63 (3.60–3.67) 0.006
HDL cholesterol, mean, mmol/L 1.44 (1.38–1.50) 1.43 (1.42–1.45) 0.891
Apolipoprotein B/apolipoprotein A1 ratio, mean 0.71 (0.67–0.74) 0.72 (0.72–0.73) 0.353
eGFR (cystatin C), mean, mL/min per 1.73 m2 74.1 (72.0–76.1) 80.1 (79.6–80.6) <0.001
hs-cTnT, GM, ng/L 7.09 (6.63–7.58) 6.43 (6.32–6.54) 0.006
NT-proBNP, GM, pg/mL 112 (95.7–131) 72.6 (69.7–75.6) <0.001
hsCRP, GM, mg/L 3.06 (2.55–3.68) 1.51 (1.44–1.58) <0.001
Triglycerides, GM, mmol/L 1.37 (1.25–1.50) 1.24 (1.21–1.27) 0.043
Data are standardized to the standard European population 2013. AUDIT indicates Alcohol Use Disorders Identiﬁcation Test; BMI, body mass index; eGFR, estimated glomerular ﬁltration
rate; GM, geometric mean; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; LDL, low-density lipoprotein; NT-proBNP, N-
terminal pro-B-type natriuretic peptide; CAGE, Cut down, Annoyed, Guilty, Eye Opener.
*All participants from the narcology clinic sample are current drinkers, but they were not drinking during the period of admission to the narcology clinic.
†Twice weekly or more frequency of hangover and/or excessive drunkenness and/or sleeping in clothes at night because of drunkenness and/or failing their family or personal obligations
because of drinking and/or drinking nonbeverage alcohols (sources of ethanol not intended for drinking, such as medicinal tinctures) and/or ≥1 episodes of zapoi (a period of ≥2 days of
being drunk, during which a participant is withdrawn from normal social life).
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additional set of variables that are likely to be the mediators
of the association between extremely heavy alcohol use and
cardiac injury (determined via hs-cTnT) had only a minor effect
on parameter estimates (Table 4).
Harmful drinkers in the general population had an elevated
concentration of NT-proBNP by 31.5% (95% CI, 3.4%–67.2%)
compared with nonproblem drinkers, but to lesser extent than
in the narcology clinic subsample (46.7%; 95% CI, 26.8%–
69.8%), controlling for age, sex, smoking, and education.
Adjustment for potential mediators of the association
between excessive alcohol use and cardiac wall stretch
(measured by NT-proBNP) resulted in some attenuation of the
effect estimate (Table 4).
The elevation of low-grade systemic inﬂammation marker
hsCRP by 69.2% (95% CI, 43%–100%) was observed in the
narcology clinic subsample compared with nonproblem
drinkers in the general population sample, controlled for
age, sex, smoking, and education. Intermediate elevations
were also seen for harmful drinkers. Further adjustment for
covariates that are likely to be on the mediation pathway
between alcohol use and hsCRP leads to increases in the
regression coefﬁcient (Table 4).
Although we did not observe increased levels of cardiac
biomarkers in the group of hazardous drinkers in the general
population, the trend test across all drinking categories
(excluding nondrinkers) was signiﬁcant for NT-proBNP and
hsCRP, with concentration of biomarkers higher with higher
level of alcohol exposure (Table 4).
Sensitivity Analysis
hs-cTnT assays are known to show appreciable imprecision at
the low values seen in the general population.38 The
interassay coefﬁcient of variation for values below the limit
Table 2. Descriptive Measures of Alcohol Use by Categories of Alcohol Use
Variables
Narcology Clinic
Sample (n=271)
General Population Sample
P
Value†
Harmful
Drinkers (n=71)
Hazardous
Drinkers
(n=424)
Nonproblem
Drinking
(n=1632)
Nondrinkers*
(n=227)
Combined biomarker of heavy alcohol use (GGT and CDT)
≥4, N (%)
135 (50.9) 27 (38.6) 55 (14.0) 23 (5.2) 0 <0.001
Have asked for help of narcologist or social worker for
drinking problem, N (%)
271 (100) 26 (36.6) 27 (6.4) 12 (0.8) 19 (23.2)§ <0.001
Drinking >40 g of alcohol per day, N (%)‡ 62 (23.7) 26 (36.6) 48 (11.3) 12 (0.7) 0 <0.001
Binge drinking (60 g of alcohol per drinking occasion) at
least once a month, N (%)
189 (70.5) 49 (69.0) 215 (51.9) 76 (4.8) 0 <0.001
Alcohol consumed per year, mean, L‡ 15.0 19.0 8.5 1.9 0 <0.001
Alcohol consumed per day, mean, g‡ 33.45 40.09 18.41 4.04 0.00 <0.001
GGT, U/L 68.02 44.39 38.48 25.03 23.69 <0.001
CDT, % 1.64 1.60 0.94 0.74 0.53 <0.001
CDT indicates carbohydrate-deﬁcient transferrin; GGT, c-glutamyl transferase.
*Nondrinkers include lifetime abstainers and ex-drinkers.
†Test for linear trend, adjusted for age and sex.
‡Alcohol consumption recorded for the past 12 months.
§Among ex-drinkers.
Table 3. Percentage Differences in hs-cTnT, NT-proBNP, and hsCRP Between Narcology Clinic Subsample and General Population
Narcology Clinic
Subsample vs
General Population
% Difference (95% CI),
Adjusted for Age
and Sex
% Difference (95% CI),
Additionally Adjusted for
Smoking and Education
% Difference (95% CI),
Additionally Adjusted for
Mediators*
hs-cTnT (n=2595) 8.2 (2.6–14.3) 12.3 (5.9–19.1) 12 (5.7–18.7)
NT-proBNP (n=2595) 63.3 (43.8–85.5) 43.9 (25.4–65.1) 30.9 (14.6–49.6)
hsCRP (n=2562) 107.2 (78.8–140.2) 66.0 (41.7–94.5) 98.3 (71.2–129.8)
Dependent variable was ln transformed, and the regression coefﬁcients were back transformed and presented as percentage difference in mean in comparison to the reference group.
hsCRP indicates high-sensitivity C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
*Possible mediators included were systolic and diastolic blood pressure, use of blood pressure medication, lipid proﬁle (total cholesterol, low-density lipoprotein cholesterol, high-density
lipoprotein cholesterol, apolipoprotein A1, and apolipoprotein B), renal function (estimated glomerular ﬁltration rate), body mass index, and waist/hip ratio.
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of quantiﬁcation (13 ng/L) was 15%. To ensure the robust-
ness of conclusions about hs-cTnT, we conducted a sensitivity
analysis using logistic regression, with hs-cTnT categorized
into values below and above the top quintile in the general
population sample (9.34 ng/L). The results of this analysis
were consistent with analyses presented above (Table S1).
Table 4. Percentage Differences in hs-cTnT, NT-proBNP, and hsCRP Between Levels of Alcohol Use
Alcohol Use
% Difference (95% CI),
Adjusted for Age and Sex
% Difference (95% CI),
Additionally Adjusted for
Smoking and Education
% Difference (95% CI),
Additionally Adjusted for
Mediators*
hs-cTnT (n=2595)
Narcology clinic subsample 6.6 (0.7 to 12.8) 10.3 (3.7 to 17.4) 10.3 (3.7 to 17.3)
Harmful drinkers, general
population sample
14.4 (22.6 to 5.3) 11.5 (20.1 to 2) 9.6 (18.2 to 0.1)
Hazardous drinkers, general
population sample
3.3 (7.7 to 1.4) 2.6 (7.1 to 2.1) 1.8 (6.3 to 2.8)
Nonproblem drinking, general
population sample
0 (Reference group) 0 (Reference group) 0 (Reference group)
Nondrinkers, general
population sample
2.1 (3.6 to 8.2) 1.6 (4.1 to 7.7) 0.6 (6.1 to 5.1)
P value for linear trend
(among drinkers)
0.272 0.068 0.047
P value for heterogeneity <0.001 <0.001 <0.001
NT-proBNP (n=2595)
Narcology clinic subsample 68.6 (47.6 to 92.6) 46.7 (26.8 to 69.8) 34.9 (17.1 to 55.4)
Harmful drinkers, general
population sample
45.6 (14.9 to 84.6) 31.5 (3.4 to 67.2) 30.1 (3.5 to 63.5)
Hazardous drinkers, general
population sample
1.5 (9.1 to 13.3) 3.5 (13.7 to 7.8) 1.9 (8.4 to 13.3)
Nonproblem drinking, general
population sample
0 (Reference group) 0 (Reference group) 0 (Reference group)
Nondrinkers, general
population sample
10.3 (3.7 to 26.4) 6.6 (6.9 to 22.1) 0.9 (11.3 to 14.8)
P value for linear trend
(among drinkers)
<0.001 <0.001 <0.001
P value for heterogeneity <0.001 <0.001 <0.001
hsCRP (n=2562)
Narcology clinic subsample 117.1 (86.1 to 153.2) 69.2 (43 to 100.2) 99.7 (70.9 to 133.4)
Harmful drinkers, general
population sample
33.9 (2.2 to 75.4) 13.4 (13.7 to 49) 28.4 (0.2 to 64.6)
Hazardous drinkers, general
population sample
14.7 (1.1 to 30.2) 6.9 (5.8 to 21.4) 0.5 (10.5 to 12.9)
Nonproblem drinking, general
population sample
0 (Reference group) 0 (Reference group) 0 (Reference group)
Nondrinkers, general
population sample
9 (22.1 to 6.4) 12.2 (24.8 to 2.5) 10.7 (22.4 to 2.8)
P value for linear trend
(among drinkers)
<0.001 <0.001 <0.001
P value for heterogeneity <0.001 <0.001 <0.001
Dependent variable was ln transformed, and the regression coefﬁcients were back transformed and presented as percentage difference in mean in comparison to the reference group.
hsCRP indicates high-sensitivity C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
*Possible mediators included were systolic and diastolic blood pressure, use of blood pressure medication, lipid proﬁle (total cholesterol, low-density lipoprotein cholesterol, high-density
lipoprotein cholesterol, apolipoprotein A1, and apolipoprotein B), renal function (estimated glomerular ﬁltration rate), body mass index, and waist/hip ratio.
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Separating the category of nondrinkers into never drinkers
and ex-drinkers for regression analysis did not reveal any
speciﬁc differences in biomarkers between these 2 groups;
therefore, the results were presented keeping current
nondrinkers as one group.
In a further sensitivity analysis, we excluded those with
previous myocardial infarction, operations on the heart, and
grade 2 angina (N=307 [11.73%]) to see if elevated cardiac
injury and cardiac wall stretch biomarkers were secondary to
coronary heart disease. This had no material effect on the
associations observed.
Discussion
In this study, we have shown that markers of cardiac injury
hs-cTnT, cardiac wall stretch NT-proBNP, and general inﬂam-
mation hsCRP are substantially elevated among those receiv-
ing treatment for alcohol problems at the narcology clinic
compared with the general population. Most important, there
was a signiﬁcant linear increasing trend of NT-proBNP across
4 groups of drinkers: nonproblem drinkers, hazardous
drinkers, harmful drinkers, and the narcology clinic sample.
Similarly, there was a linear increase in hsCRP levels over
drinking groups.
NT-proBNP has been developed and primarily used in the
clinical contexts of diagnosis and prognosis of heart failure.5
However, in population-based samples, low-grade elevation in
NT-proBNP was shown to be an early marker of cardiac injury
that is not yet clinically evident.6,39 In this study, we showed
markedly elevated levels of NT-proBNP in the sample
receiving treatment at a narcology clinic and intermediate
elevation in the general population sample of harmful
drinkers. This is consistent with a previous report from the
Izhevsk family study and the Belfast (UK) component of the
PRIME (Prospective Epidemiological Study of Myocardial
Infarction) study that showed elevated NT-proBNP in haz-
ardous drinkers.40 This ﬁnding is further supported by
increased risk of heart failure among heavy drinking men in
the prospective BRHS (British Regional Heart Study).24
However, our study goes further by showing that there is a
biomarker dose-response effect across the 4 categories of
heavy drinking at levels of NT-proBNP that are below clinical
thresholds for heart failure. Other studies of this question that
had inconsistent ﬁndings were limited by the fact that the
populations they studied had much lower levels of alcohol
consumption.18,21,23
After the adjustment for the possible mediators of the
association between alcohol use and NT-proBNP (blood
pressure, blood lipid indexes, BMI, and kidney function), the
regression coefﬁcients were partly attenuated. This could be
explained by an effect of alcohol on kidney function because it
was shown that risk of chronic kidney disease is higher in
people with alcohol use disorder.41 Increased blood pressure
caused by heavy alcohol use42,43 may be responsible for a
decrease in kidney function and may lead to hypertensive
cardiac injury. Low BMI and altered lipid metabolism in the
narcology clinic subsample, caused by alcoholic malnutrition,
poor diet, and effects of alcohol, may further contribute to the
damage of the myocardium.
The direct toxic effect of alcohol on the heart as a result of
persistent heavy drinking is an established mechanism of
alcoholic cardiomyopathy.44 The condition can be undiag-
nosed, interact with the atherosclerotic damage to cardiovas-
cular system, and increase the risk of sudden cardiac death.1
Estimates of the risk of diagnosed alcoholic cardiomyopathy in
people with alcohol use disorders varied between 1% and 40%,
depending on the patient population studied.44 The observed
increasing trend in NT-proBNP levels across 4 categories of
alcohol exposure in our study gives support to the hypothesis
that heavy drinking causes subclinical nonischemic myocardial
damage. The association of heavy alcohol use with NT-proBNP
in our study is consistent with previous reports of increased NT-
proBNP in left ventricular hypertrophy, atrial ﬁbrillation, and
stroke.7–9
Cardiac troponin T elevation is a biomarker used for the
diagnosis of acute myocardial infarction. Development of the
testing technology and introduction of hs-cTnT tests led to
recognition that low-grade elevations of hs-cTnT are predic-
tive of future cardiovascular events and death in general
population.4,6,45 Detectable hs-cTnT is observed in a sizable
proportion of individuals without diagnosis of CVD.18 In our
study, detectable levels of hs-cTnT were observed in 98% of
the study sample, which is higher than in some other
population-based cohorts,6,46 but comparable to others.19 It
has been suggested that long-term elevation of hs-cTnT is
explained to a greater extent by indexes of heart failure (eg,
higher left ventricular mass and lower left ventricular
ejection fraction) and increased NT-proBNP levels than
indexes of atherosclerosis or ischemia.46,47 Also, hs-cTnT
has been found to be a direct marker of ongoing myocardial
ﬁbrosis.48 Similarly, in our sample of heavy drinkers at the
narcology clinic, elevation of hs-cTnT may indicate nonis-
chemic injury to the myocardium that occurred because of
exposure to high doses of alcohol or its metabolites, such as
acetaldehyde. After adjustment for possible mediators (blood
pressure, blood lipid indexes, BMI, and kidney function), the
regression coefﬁcients for the relationship between heavy
alcohol use and hs-cTnT did not change. Therefore, the
effect of heavy alcohol consumption on the myocardium may
be explained by the direct injury of myocardium by alcohol
or its metabolites that leads to cell death. However, it is
unclear why the group of harmful drinkers in the general
population have lower levels than nonproblem drinkers,
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although the CIs around the estimates of effect for hs-cTnT
are large. A literature search for other studies that looked at
association between alcohol consumption and hs-cTnT
identiﬁed only reports with relatively moderate level of
alcohol use, which reported either decreased or the same
hs-cTnT levels in some groups of drinkers compared with
nondrinkers.18,21–23 The reasons for this phenomenon may
lie in low precision of hs-cTnT at low levels, unknown factors
inﬂuencing the performance of the test, and selection of the
comparison group for analysis by categories of alcohol
consumption.
A U-shaped relation between alcohol intake and CRP was
previously observed, with heavy drinkers showing higher
CRP than moderate drinkers.49,50 The elevation of CRP in
our study in the narcology clinic sample and the trend for
elevated hsCRP across harmful and hazardous drinkers in
the general population may have several explanations. The
low-grade elevation of hsCRP in individuals with no overt
disease is nonspeciﬁc and may reﬂect exposure to proin-
ﬂammatory inﬂuences, including smoking, particulate air
pollutants, aspects of diet, medications, obesity, and the
metabolic syndrome.13 Although we made efforts to adjust
for many of these factors, there is still a strong possibility
of residual confounding. Beyond this, there are several
explanations for increased hsCRP in the narcology clinic
subsample, including, but not limited to, toxic effects of
alcohol and its metabolites on the liver, ranging from fatty
liver to steatosis, process of detoxiﬁcation, and exposure to
the speciﬁc medications during treatment for alcohol
problems. Finally, elevated levels of hsCRP in the narcology
clinic subsample and the trend across categories of drinkers
in the general population may be secondary to an
atherosclerotic process facilitated by harmful and hazardous
drinking. Thus, it is not possible from our study to
determine which of these various explanations may account
for the association of hsCRP with harmful and hazardous
patterns of drinking.
Strengths and Limitations
Our study has several strengths that make it a signiﬁcant
contribution to the body of evidence on detrimental effects of
alcohol on cardiovascular health by relating harmful and
hazardous alcohol use to the markers of cardiac damage,
cardiac wall stretch, and low-grade inﬂammation. We were
able to recruit a substantial number of participants with
substantial variation in the level and intensity of alcohol
drinking. In addition, this study has addressed a gap in the
research literature about the impact of high levels of exposure
on cardiac injury44 in a country where this exposure is
relatively common25 and rates of CVD mortality are among
the highest in the world.26
Previous studies of association between alcohol consump-
tion and CVD biomarkers are few and done in populations
with relatively moderate quantities of consumed alcohol,
whereas this study was able to differentiate between different
patterns of heavy alcohol use, including extreme drinking
patterns commonly observed in patients treated in Russian
state-run narcology services. Although patients there may
experience multiple comorbidities, they are most likely the
consequence of an extremely heavy pattern of alcohol use.
Their admission to the narcology clinic was because of the
need for detoxiﬁcation rather than organic comorbidities.
Therefore, it is a good setting to study the mechanisms of
cardiac injury caused by heavy alcohol use; and the results
are likely to be generalizable to all countries and populations.
A particular strength of our study is that the collection of
detailed questionnaire information on patterns and quantities
of alcohol consumption during the past year has allowed us to
construct a plausible grouping of general population partic-
ipants according to degree of harmfulness of their alcohol
consumption with strong face validity. Moreover, our ability to
separate nondrinkers from nonproblem drinkers and the
availability of data on confounders beyond age and sex have
minimized the bias common to many other studies on alcohol
drinking and CVD.51 We cannot fully exclude the possibility of
some residual confounding by smoking that was measured by
self-report. Acknowledging the limitation of cross-sectional
studies to show the direction of the association, we look
forward to the prospective studies that may give better
support for our conclusions.
Conclusions
The elevated levels of both NT-proBNP and hs-cTnT in the
group of extremely heavy drinkers from the narcology
subsample are consistent with heavy alcohol drinking leading
to nonischemic damage of the heart. Elevated NT-proBNP in
harmful drinkers from the general population provides further
evidence for this. Furthermore, exclusion of individuals who
had a previous diagnosis of coronary heart disease did not
have an impact on the substantive results. However, this
study cannot deﬁnitively exclude that heavy drinking may also
contribute to increased CVD risk through ischemic pathways,
as could be indicated by elevated hsCRP. The signiﬁcance of
ﬁndings in this study and the relative importance of different
pathophysiological processes in harmful and hazardous
drinkers should be further investigated using heart imaging
methods. Echocardiography and cardiac magnetic resonance
imaging can give more information about signiﬁcance of
cardiomyopathy-related indexes in excessive drinkers. Com-
puterized tomography coronary angiogram or carotid ultra-
sound will allow direct measurement of the extent of
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atherosclerosis and will answer the question about signiﬁ-
cance of elevated hsCRP levels in harmful and hazardous
drinkers.
The results of this study help to explain why heavy alcohol
drinking has been related to excess mortality in Russia if
considered in the context of previous studies exploring causes
of high cardiovascular mortality in Russia.31 Public health
researchers and practitioners need to take account of the
cardiotoxic effects of heavy drinking in populations, even
when the levels of diagnosed frank alcoholic cardiomyopathy
may be relatively low.
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Table S1. Association of high values of hs-cTrT (above 9.34 ng/L) with levels of alcohol use (logistic regression analysis). 
 Model 1 
(adjusted for age and sex), 
OR (95% CI) 
Model 2 
(additionally adjusted for 
smoking and education), OR 
(95% CI) 
Model 3 
(additionally adjusted for 
other covariates), OR (95% 
CI) 
hsTrT, N = 2595.    
Alcohol use    
Narcology clinic subsample 1.72 (1.22, 2.44) 2.01 (1.36, 2.97) 2.25 (1.5, 3.39) 
General population sample, harmful drinkers 0.38 (0.17, 0.84) 0.46 (0.2, 1.03) 0.48 (0.21, 1.1) 
General population sample, hazardous drinkers 0.91 (0.68, 1.23) 0.92 (0.68, 1.25) 0.92 (0.67, 1.26) 
General population sample, non-problem drinking 1.0 [reference group] 1.0 [reference group] 1.0 [reference group] 
General population sample, non-drinkers  1.03 (0.72, 1.47) 0.99 (0.69, 1.43) 0.89 (0.61, 1.3) 
P-value for trend test (among drinkers), df=1 0.132 0.0734 0.032 
P-value for heterogeneity test, df=4 < 0.001 < 0.001 < 0.001 
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Figure S1. The directed acyclic graph (DAG) depicting the suggested causal relationship between heavy alcohol use and heart damage 
(hs-cTrT serving as a biomarker). 
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Figure S2. The directed acyclic graph (DAG) depicting the suggested causal relationship between heavy alcohol use and cardiac wall 
stretch (NT-proBNP serving as a biomarker). 
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Figure S3. The directed acyclic graph (DAG) depicting the suggested causal relationship between heavy alcohol use and systemic 
inflammation (hsCRP serving as a biomarker). 
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